home / stock / crnx / crnx news

CRNX News and Press, Crinetics Pharmaceuticals Inc. From 03/19/19

Stock Information
Company Name: Crinetics Pharmaceuticals Inc.
Stock Symbol: CRNX
Market: NASDAQ
Website: crinetics.com
Menu
CRNX CRNX Quote CRNX Short CRNX News CRNX Articles CRNX Message Board
Get CRNX Alerts

News, Short Squeeze, Breakout and More Instantly...
CRNX - Crinetics doses first patients in phase 2 clinical trials of CRN00808

Crinetics Pharmaceuticals (NASDAQ: CRNX ) begins patients dosing in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly. More news on: Crinetics Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

CRNX - Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly

SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced ...

CRNX - Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning

SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced t...

CRNX - Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019

SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced f...
CRNX - Crinetics Pharmaceuticals beats on revenue

Crinetics Pharmaceuticals (NASDAQ: CRNX ): Q4 GAAP EPS of -$0.35. More news on: Crinetics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

CRNX - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported fi...

CRNX - Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced th...
CRNX - Crinetics Pharmaceuticals Seeks To Supplant Big Pharma Competition In Acromegaly

Shares of Crinetics Pharmaceuticals ( CRNX ) have risen by over 40% since its IPO pricing at $17 in July of 2018. Year to date the stock has lost 18% of its value (perhaps due to a lack of news flow). Given the strong slate of institutional investors involved here and an intriguing pipelin...

Previous 10 Next 10